SNY Quote, Financials, Valuation and Earnings

Innate Pharma SA has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Innate Pharma SA's return on equity of -72.79%.

Sanofi SA has a consensus price target of $64.64, signalling upside risk potential of 23.66%. On the other hand Innate Pharma SA has an analysts' consensus of $7.84 which suggests that it could grow by 229.92%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.546, which suggesting that the stock is 45.374% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.329%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.53%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Innate Pharma SA quarterly revenues of --. Sanofi SA's net income of $2B is higher than Innate Pharma SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 18.64x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 14.22x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 17.65% compared to Sanofi SA's net margin of -907.48%. Sanofi SA's return on equity of 8.47% beat Moderna's return on equity of -29.23%.

Sanofi SA has a consensus price target of $64.64, signalling upside risk potential of 23.66%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 95.19%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.546, which suggesting that the stock is 45.374% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.53%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Moderna quarterly revenues of $107M. Sanofi SA's net income of $2B is higher than Moderna's net income of -$971M. Notably, Sanofi SA's price-to-earnings ratio is 18.64x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 2.98x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 17.65% compared to Sanofi SA's net margin of -91.76%. Sanofi SA's return on equity of 8.47% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of $64.64, signalling upside risk potential of 23.66%. On the other hand Novavax has an analysts' consensus of $15.57 which suggests that it could grow by 161.71%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.546, which suggesting that the stock is 45.374% less volatile than S&P 500. In comparison Novavax has a beta of 3.210, suggesting its more volatile than the S&P 500 by 220.956%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.53%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Novavax quarterly revenues of $88.3M. Sanofi SA's net income of $2B is higher than Novavax's net income of -$81M. Notably, Sanofi SA's price-to-earnings ratio is 18.64x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 1.37x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 17.65% compared to Sanofi SA's net margin of 26.7%. Sanofi SA's return on equity of 8.47% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Sanofi SA has a consensus price target of $64.64, signalling upside risk potential of 23.66%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 42.64%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.546, which suggesting that the stock is 45.374% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Sanofi SA has a quarterly dividend of $2.04 per share corresponding to a yield of 7.53%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Sanofi SA's net income of $2B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Sanofi SA's price-to-earnings ratio is 18.64x while Regeneron Pharmaceuticals's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.68x versus 4.54x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.